Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 6.43
(0.94%)
CNY 6.43
(0.94%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 56.65 Million CNY | -59.39% |
| 2022 | 139.49 Million CNY | -24.66% |
| 2021 | 185.15 Million CNY | 145.98% |
| 2020 | 75.27 Million CNY | 32354.58% |
| 2019 | 231.93 Thousand CNY | 65.55% |
| 2018 | 140.09 Thousand CNY | -99.4% |
| 2017 | 23.45 Million CNY | 134.52% |
| 2016 | 10 Million CNY | 2727.23% |
| 2015 | 353.7 Thousand CNY | -28.1% |
| 2014 | 491.94 Thousand CNY | -98.76% |
| 2013 | 39.71 Million CNY | 12252.89% |
| 2012 | 321.48 Thousand CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 77.55 Million CNY | 44.88% |
| 2024 Q3 | 81.05 Million CNY | 12.44% |
| 2024 Q1 | 53.53 Million CNY | -5.5% |
| 2023 Q3 | 118.28 Million CNY | -18.16% |
| 2023 Q4 | 56.65 Million CNY | -52.11% |
| 2023 FY | 56.65 Million CNY | -59.39% |
| 2023 Q1 | 137.82 Million CNY | -1.19% |
| 2023 Q2 | 144.54 Million CNY | 4.87% |
| 2022 Q4 | 139.49 Million CNY | 50.78% |
| 2022 FY | 139.49 Million CNY | -24.66% |
| 2022 Q1 | 85.99 Million CNY | -53.55% |
| 2022 Q2 | 206.26 Million CNY | 139.85% |
| 2022 Q3 | 92.51 Million CNY | -55.15% |
| 2021 Q3 | 257.81 Million CNY | 35.95% |
| 2021 Q2 | 189.63 Million CNY | 95.5% |
| 2021 Q4 | 185.15 Million CNY | -28.18% |
| 2021 FY | 185.15 Million CNY | 145.98% |
| 2021 Q1 | 97 Million CNY | 28.87% |
| 2020 Q1 | 81.27 Million CNY | 34941.56% |
| 2020 Q4 | 75.27 Million CNY | 0.0% |
| 2020 FY | 75.27 Million CNY | 32354.58% |
| 2020 Q2 | 81.27 Million CNY | 0.0% |
| 2020 Q3 | 75.27 Million CNY | -7.38% |
| 2019 Q1 | 133.37 Thousand CNY | -4.8% |
| 2019 FY | 231.93 Thousand CNY | 65.55% |
| 2019 Q3 | 215.15 Thousand CNY | -4.4% |
| 2019 Q4 | 231.93 Thousand CNY | 7.8% |
| 2019 Q2 | 225.05 Thousand CNY | 68.74% |
| 2018 FY | 140.09 Thousand CNY | -99.4% |
| 2018 Q4 | 140.09 Thousand CNY | 0.0% |
| 2018 Q3 | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2017 Q3 | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | 23.45 Million CNY | 134.52% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 Q2 | 10.14 Million CNY | 0.0% |
| 2016 Q4 | 10 Million CNY | 0.0% |
| 2016 FY | 10 Million CNY | 2727.23% |
| 2015 FY | 353.7 Thousand CNY | -28.1% |
| 2014 FY | 491.94 Thousand CNY | -98.76% |
| 2013 FY | 39.71 Million CNY | 12252.89% |
| 2012 FY | 321.48 Thousand CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.29 Billion CNY | 98.68% |
| Hangzhou Tigermed Consulting Co., Ltd. | 3.34 Billion CNY | 98.307% |
| Dirui Industrial Co.,Ltd. | 714.1 Million CNY | 92.067% |
| Beijing Strong Biotechnologies, Inc. | 1.13 Billion CNY | 95.011% |
| Medicalsystem Biotechnology Co., Ltd. | 108.17 Million CNY | 47.627% |
| Maccura Biotechnology Co.Ltd | 665.16 Million CNY | 91.483% |
| Guangzhou Wondfo Biotech Co.,Ltd | 599.53 Million CNY | 90.551% |
| BGI Genomics Co., Ltd. | 1.09 Billion CNY | 94.833% |
| Amoy Diagnostics Co., Ltd. | 108.34 Million CNY | 47.712% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 374.62 Million CNY | 84.877% |